A PMTA, or Premarket Tobacco Product Application, is the FDA’s required review process for any new tobacco product before it can be legally sold in the United States. If a company wants to bring a vape, e-cigarette, cigar, or other tobacco product to market, it must submit scientific evidence proving the product is “appropriate for the protection of public health.” Without an authorized PMTA, a tobacco product is considered illegal to sell.
How the PMTA Came About
The legal foundation for PMTAs is the Family Smoking Prevention and Tobacco Control Act, passed in 2009, which gave the FDA authority to regulate tobacco products. Initially, that authority covered cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. In 2016, the FDA published the Deeming Rule, which extended its reach to all other tobacco products meeting the legal definition. That included electronic cigarettes, e-liquids, cigars, pipe tobacco, and hookah tobacco.
The Deeming Rule meant that thousands of products already on store shelves, particularly e-cigarettes and vape products, suddenly needed FDA authorization to remain on the market. Manufacturers were given deadlines to submit PMTAs, and those that failed to do so or received denials faced enforcement action.
What the FDA Looks For
The central question in every PMTA review is whether the product benefits public health overall, not just the individual using it. The FDA weighs several factors when making that call:
- Risks and benefits to the whole population, including both users and nonusers
- Impact on current tobacco users: whether the product makes people more or less likely to quit tobacco altogether
- Impact on nonusers: whether the product would attract people, especially young people, who don’t currently use tobacco
- Manufacturing quality: the methods, facilities, and controls used to make and package the product
This population-level standard is critical. A product might help some adult smokers reduce their exposure to harmful chemicals, but if it simultaneously attracts large numbers of teenagers who wouldn’t otherwise use nicotine, the FDA can determine that the net effect on public health is negative and deny the application.
What a PMTA Must Include
Submitting a PMTA is not a simple form. Applications require full reports of all published and known investigations into the product’s health risks, including whether the product presents less risk than other tobacco products. Companies must also submit studies on how consumers perceive the product and whether it would influence their intentions to start or stop using tobacco. The FDA calls these “tobacco product perception and intention” studies, and they’re designed to capture the real-world appeal of the product, particularly to young people.
Beyond health data, applicants must address environmental impacts. The FDA requires an environmental assessment covering the product’s use and disposal, including things like how discarded cartridges, batteries, or packaging affect the environment. An incomplete environmental assessment can cause the FDA to refuse the application before substantive review even begins.
How the PMTA Differs From Other Pathways
The PMTA is one of three ways a tobacco product can reach the market, and it’s the most comprehensive. The other two are the Substantial Equivalence pathway and the Exemption from Substantial Equivalence.
Substantial Equivalence lets a manufacturer show that its new product is essentially the same as a product already legally on the market (called a “predicate product”). The PMTA, by contrast, does not require any comparison to an existing product. It stands entirely on its own scientific evidence. This makes it the primary pathway for genuinely novel products like e-cigarettes that have no clear predicate.
There’s also a separate process called the Modified Risk Tobacco Product Application, which is specifically for products that want to be marketed with claims about reduced harm or disease risk. If a modified risk product is also a new tobacco product, it still needs to go through one of the three marketing pathways (including the PMTA) before it can be sold.
Most Applications Have Been Denied
The FDA has denied far more PMTAs than it has approved, particularly for flavored e-cigarette products. In one round alone, the agency issued marketing denial orders to 10 companies covering approximately 6,500 flavored e-liquid and e-cigarette products. The reason cited in those cases: the applicants failed to provide sufficient scientific evidence that their flavored products would benefit public health.
The FDA has been explicit that no flavored e-cigarette product has cleared the bar of scientific sufficiency to date. The agency’s position is that while tobacco-flavored e-cigarettes may help some adult smokers transition away from combustible cigarettes, flavored products carry a much higher risk of attracting young nonusers, and applicants haven’t provided enough data to overcome that concern.
The small number of products that have received marketing authorization tend to be tobacco-flavored e-cigarettes from major manufacturers who invested heavily in long-term clinical and behavioral studies.
Enforcement Against Unauthorized Products
Products on the market without an authorized PMTA are considered both adulterated and misbranded under federal law. The FDA has made clear it has not adopted any broad policy of looking the other way. Even having a pending application does not create a legal safe harbor to keep selling a product.
In practice, the FDA generally follows a stepped enforcement approach. It typically starts with a warning letter, giving the company a chance to respond. If a follow-up inspection finds continued violations, the agency can escalate to civil money penalties. In more serious cases, the FDA can pursue seizure of products or seek a court injunction to stop a company from selling unauthorized products entirely. The agency decides whether to act on a case-by-case basis, with youth use being a major factor in prioritizing targets.
A limited number of products that received denial orders are still on shelves because courts granted temporary stays while legal challenges play out, or because the FDA itself is conducting further review. Those are exceptions, not the norm.